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Abstract
It is well established that paracrine secretion of anti-viral CCR5 ligands by CD8
+ and CD4
+ T cells can block the infection of
activated CD4
+ T cells by R5 and dual-tropic isolates of HIV-1. By contrast, because CD4
+ T cells can be infected by HIV-1 and
at least some subsets secrete anti-viral CCR5 ligands, it is possible that these ligands protect against HIV-1 via autocrine as
well as paracrine pathways. Here we use a model primary CD4
+ T cell response in vitro to show that individual CD4
+ T cells
that secrete anti-viral CCR5 ligands are ‘self-protected’ against infection with R5 but not X4 strains of HIV-1. This protection
is selective for CD4
+ T cells that secrete anti-viral CCR5 ligands in that activated CD4
+ T cells in the same cultures remain
infectable with R5 HIV-1. These data are most consistent with an autocrine pathway of protection in this system and indicate
a previously unappreciated selective pressure on the emergence of viral variants and CD4
+ T cell phenotypes during HIV-1
infection.
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Introduction
It has been known for over a decadethat CD8
+ T cells secretethe
anti-viral CCR5 ligands, CCL3 (MIP-1a), CCL4 (MIP-1b), and
CCL5 (RANTES), which block the infection of CCR5+ cells by R5
viruses in vitro ([1] and reviewed in [2]). Since then, a number of
studies have implicated anti-viral CCR5 ligands in protective
immunity against HIV-1 in the clinical settings of exposed
uninfected cohorts [3,4], neonatal transmission [5], and progression
to AIDS [6–9]. Shortly after the original discovery that CD8
+ T
cells synthesize anti-viral CCR5 ligands a study appeared indicating
that CD4
+ T cells also secrete these molecules [10]. Several
subsequent studies suggested that synthesis of CCR5 ligands by ex
vivo CD4
+ T cellscorrelateswithresistance ofthesecellstoinfection
and indicated an inverse relationship between CCR5 ligand
synthesis and lower co-receptor levels [3,11–13]. These studies
did not place CCR5 ligand synthesis into a precise immunological
contextdefinedby the response phase (i.e., primary or secondary) or
CD4
+ T cell subsets synthesizing the ligands.
To this end, our group [14,15] and another [16,17] reported the
synthesis of a CCR5 ligand, CCL4, by memory CD4
+ T cell
subsets in uninfected volunteers. Interestingly, the frequencies of
memory CD4
+ T cells that synthesize CCL4 in response to
antigenic stimulation were substantially lower than those found for
CD8
+ T cells [14,16]. Collectively, these studies show that CD4
+
T cells can synthesize anti-viral CCR5 ligands during the memory
phase of an adaptive immune response, although CD8
+ T cell
subsets might be the predominant source of these molecules at this
point in the adaptive immune response. Less is known about the
synthesis of anti-viral CCL5 ligands during the primary CD4
+ T
cell response.
To address this issue, we established an in vitro model of the
primary antigen specific CD4
+ T cell response in which purified
naı ¨ve CD4
+ T cells from healthy people are co-cultured with
monocyte derived dendritic cells (MDDC) plus antigen [18]. The
subsequent immune response was measured in vitro by activation
parameters including the synthesis of anti-viral CCR5 ligands
[18]. In this report, we extend those studies by showing that
individual CD4
+ T cells which synthesize anti-viral CCR5 ligands
are ‘self-protected’ against infection with R5 but not X4 isolates of
HIV-1 during the primary immune response in vitro. These data
are most consistent with an autocrine mode of protection and
indicate previously unappreciated selective pressure on the
emergence of viral variants and CD4
+ T cell phenotypes during
HIV-1 infection.
Materials and Methods
Reagents
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-HypaqueH centrifugation using blood obtained from normal
healthy volunteers either through commercial sources or by
venipuncture of healthy adult volunteers under approval of the
University of Maryland Institutional Review Board or through
commercial sources. The following fluorochrome-labeled antibod-
ies were purchased from BD Biosciences (San Jose, CA): CD4-
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The antibodies against HIV1 p24 (KC57-RD and KC57-FITC)
were obtained from Beckman Coulter (Miami, FL). Neutralizing
goat antibodies specific for CCL3, CCL4, and CCL5, along with
normal goat IgG, were from R&D Systems (Minneapolis, MN).
Staphylococcus enterotoxin B (SEB) was purchased from Sigma
(St. Louis, MO).
Preparation of Virus Stocks
HIV-1 stocks (four R5 viruses: HIV-1Ba-L, HIV-192BR020, HIV-
1Jv1083, HIV-1SF162; three R5/X4 viruses: HIV-189.6, HIV-
192HT594, and HIV-1BZ167; four X4 viruses: HIV-192ug024, HIV-
1Lai, HIV-1IIIB, HIV-12044) were obtained originally from the
NIAID AIDS Reference and Research Reagent Repository
(Kensington, MD). Working viral stocks were prepared for this
study by infection of CD8-depleted PHA-stimulated PBMCs from
a single donor using seed stocks maintained in the uQuant Core
Facility at the Institute of Human Virology.
Viral Infection During Primary CD4
+ T Cell Responses in
vitro
Generation of immature monocyte-derived dendritic cells
(MDDC) and the culture system for generating primary in vitro
CD4+ T cell responses were described in detail previously [18]. In
this system, highly enriched naı ¨ve (CD45RO
2 CD62L
+) CD4
+ T
cells are cultured with autologous MDDC and nominal antigen,
allogeneic MDDC (as alloantigen), or superantigens for periods of
up to three weeks. Responses are monitored by cell division by
CFSE dilution and for changes in phenotype and function by
surface markers and cytokine production, respectively. Responses
in this system are strictly dependent upon MDDC as antigen
presenting cells and foreign antigen. The ability of this system to
detect primary CD4
+ T cell responses in a clonal fashion has been
described [18]. For viral infection, 1000 TCID50 of the indicated
HIV-1 isolates were added with naı ¨ve CD4+ T cells (2610
5 per
well), MDDC (2610
3 per well) and antigen (100 ng/ml SEB) in
200 ml per well medium in U-bottom 96-well plates. In some
experiments, alloantigens were used in lieu of SEB to elicit the
primary immune response. This was accomplished by using 1610
4
allogeneic MDDC as the stimulus for naı ¨ve CD4
+ T cells. Viral
infection of MDDC was performed by co-culturing MDDC
(2610
4 per well) with 1000 TCID50 of the HIV-1 isolates as
indicated in the text. Aliquots of supernatants were removed on
days 2, 5, 8, 11, and 14 and quantified for p24 concentrations by
ELISA (New England Nuclear, Cambridge, MA). Alternatively,
viral replication was determined by intracellular staining for HIV-
1 p24 antigen as described below. Each experiment was repeated
at least twice with comparable results.
Intracellular staining
Cells were collected at the time points indicated in the Results
section and washed twice in staining buffer [PBS with 2% BSA
and 0.1% Sodium azide]. They were stained for surface markers
as indicated in the Results section, fixed, and permeabilized for
intracellular staining according to manufacturer’s instructions
using the Cytofix/Cytoperm Plus kit (BD Biosciences, San Jose,
CA). For detection of intracellular MIP1b, Golgistop reagent (BD
Biosciences, San Jose, CA) was added on day 6 for the last
10 hours of culture before collecting cells for staining as described
above. We used the KC57-FITC antibody for detection of
intracellular of HIV1 p24 antigen and MIP1b-PE antibody for
detection of intracellular CCL4. Experience has shown that it is
difficult to reliably detect the two other anti-R5 HIV-1 b-
chemokines, CCL3 and CCL5 by intracellular staining. For this
reason we were only able to follow the synthesis of CCL4 (MIP-
1b). Co-staining for p24 and CCL4 was carried out after the last
10 hours of culture in the presence of Golgistop. Data were
acquired by six-parameter flow cytometry and analyzed with
FlowJo software (Treestar, Inc., San Carlos, CA).
Results
Selective replication of X4 and R5/X4 HIV-1 during the in
vitro primary CD4
+ T cell response
The ability of R5, X4, and R5/X4 isolates of HIV-1 to replicate
in CD4
+ T cells during the primary in vitro immune response was
determined using a system developed by our group to evaluate the
synthesis of anti-viral CCR5 ligands [18], the effects of adjuvants
on antigen presentation [19–21], and the responses to HIV-1
vaccine candidates [22]. Cultures were initiated and infected with
the HIV-1 isolates shown in Figure 1a as described in Materials
and Methods. As shown in Figure 1a, five of the six X4 and R5/
X4 viruses replicated by day 8 of the culture period. The R5/X4
virus HIV-189.6 replicated poorly, if at all. By contrast, none of the
four R5 viruses replicated early in the culture period with only
HIV-1SF162 showing a modest increase in p24 by day 11. Since the
differences in replication appeared to be greatest during the first
11 days of culture, we compared the day 8 median p24
concentrations of the three groups for statistical significance using
Student’s t-test. As shown in Figure 1b, the differences between the
R5 group and either the X4 or X4/R5 groups were statistically
significant (p=0.02) for X4 viruses, p#0.05 for X4/R5 viruses).
These data show that X4 and X4/R5 viruses selectively replicate
during the antigen driven primary CD4
+ T cell response in vitro
with little or no replication of R5 viruses under these experimental
conditions. This conclusion was confirmed in subsequent exper-
iments by analysis of intracellular p24.
The data from one such experiment are shown in Figure 1c and
1d where cells were harvested on day 7 from cultures established
as above for Figure 1a washed and stained for intracellular p24 as
described in Materials and Methods. Figure 1c shows typical
intracellular staining of CD4
+ CD45RO
+ T cells for intracellular
p24 for cultures infected with an R5 virus (HIV-1Ba-L), an R5/X4
virus (HIV-1BZ167), or an X4 virus (HIV-1IIIB). Note that
CD45RO marks responding cells in our assay system[18,22]. As
expected from the results on supernatant p24 (Figure 1a), no p24
staining was found for cultures infected with R5 virus, HIV-1Ba-L,
whereas p24 staining was apparent for both the R5/X4 and X4
viruses shown in Figure 1c. Staining for p24 was absent when an
inhibitory concentration AZT was included in a parallel culture
exposed to the X4 virus, showing that the observed staining
required active reverse transcription and that the p24 signal was
not due to passively adsorbed protein from the input virus.
Statistical significance of differential infection as determined by
p24 staining was assessed for the same virus panel shown in
Figure 1a using the frequencies of CD4
+ CD45RO
+ T cells that
also express p24. The results of this analysis are shown in Figure 1d
where the frequencies of CD4
+ CD45RO
+ p24
+ cells in R5
cultures were approximately 100-fold lower than those observed
for the R5/X4 and X4 virus panels. These differences were
statistically significant as determined by a two-tailed Student’s t-
test (p=0.044 and p=0.001 for comparisons of the R5 viruses
with the R5/X4 and X4 viruses, respectively). These data confirm
the conclusions reached using p24 supernatant concentrations as
the readout and show that antigen activated CD4
+ T cells are the
probable source of the virus. As the cultures were initiated with
both immature MDDC and naı ¨ve CD4
+ T cells, we cannot
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in the supernatants. However, this is unlikely given the small
number of MDDC in the cultures (1% at culture initiation) and by
additional studies in which R5 viruses selectively replicate in
cultures of immature MDDC cultured alone (Figure 2). Thus, it is
unlikely that MDDC infection accounts for our results.
Antibodies to antiviral CCR5 ligands allow the replication
of R5 HIV-1 during the primary CD4
+ T cell response in
vitro
The poor replication of R5 viruses in the experiments described
above strongly suggested that the effect is due to anti-viral CCR5
ligands made by the responding CD4
+ T cells. To test this
hypothesis, cultures were established as described in Figure 1 using
HIV-1Ba-L as the R5 virus but spiked with a mixture saturating
concentrations of blocking antibodies specific for CCL3, CCL4,
and CCL5 or non-immune goat IgG as the negative control. The
experimental groups (shown in duplicate in Figure 3a ) include
HIV-1Ba-L alone, HIV-1Ba-L with non-immune goat IgG, and
HIV-1Ba-L with the mixture of blocking goat anti-b-chemokine
IgGs (Fig. 3a, black lines). As expected, no viral replication was
observed for groups cultured with HIV-1Ba-L or HIV-1Ba-L plus
non-immune goat IgG (Figure 3a, red and magenta lines,
respectively). By contrast, viral replication was observed in the
group cultured with HIV-1Ba-L plus the mixture of goat anti-b-
chemokine IgGs. Intracellular p24 staining confirmed the presence
of viral protein synthesis in responding CD4
+ CD45RO
+ T cell
blasts (Figure 3b) in the cultures treated with the mixture of anti-b-
chemokine IgGs (right panel) but not in the cultures treated with
Figure 1. Selective replication of X4 or R5/X4 viruses during the primary in vitro CD4+ T cell response to SEB. a. Four R5 viruses (Ba-L,
92BR020, Jv1083, SF162), three R5/X4 viruses (89.6, 92HT594, BZ167) and three X4 viruses (92ug024, Lai, IIIB) were added along with naı ¨ve CD4
+ T
cells plus MDDC and SEB to initiate a primary immune response in vitro as described in Materials and Methods. The viral input was 1000 TCID50 per
culture. Viral replication was monitored by detection of HIV1 p24 antigen in supernatant and shown in red for R5 viruses, magenta for R5/X4 viruses,
and blue for X4 viruses. b. Day 8 p24 levels were pooled for each viral co-receptor family and the medians were compared for statistical significance
by a double tailed Student’s t-test. c. Representative examples are shown of p24 staining for CD4
+ CD45RO
+ T cells responding to SEB and
autologous MDDC in the presence of a R5 virus (Ba-L), a R5/X4 virus (BZ167), or a X4 virus (IIIB), the latter in the presence and absence of AZT (
10 uM). Cells were harvested on day 7 post-initiation of a primary CD4
+ T cell response in the presence of the indicated HIV-1 isolates (1000 TCID50
per culture) and stained for surface markers and p24 antigen as described in Materials and Methods. d. Median frequencies of p24+ CD4
+ CD45RO
+
cells were pooled for each co-receptor family and compared for statistical significance by a two-tailed Student’s t-test. The data are from staining
analyses carried out on day 7 cells generated in a primary CD4
+ T cell response to SEB in the presence of 1000 TCID50 of the R5, R5/X4, and X4 viruses
used in Figure 1a.
doi:10.1371/journal.pone.0003481.g001
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hypothesis that the anti-viral CCR5 ligands, CCL3, CCL4, and
CCL5, produced during the primary CD4
+ T cell response in vitro
are sufficient to severely dampen replication of an R5 virus present
continuously in the culture. They also set the stage in this culture
system for determining whether the individual CD4
+ T cells that
secrete anti-viral CCR5 ligands are ‘self-protected’ from infection
with R5 HIV-1.
Figure 2. Selective replication of R5 HIV-1 in immature MDDC. Immature MDDC cells ( 2610
4 per well) were cultured with 1000 TCID50 of the
HIV-1 viruses indicated in the figure panel as described in Methods. Supernatants were collected on days 2, 5, 8, 11 and 14 post-infection and tested
for HIV-1 p24 antigen by ELISA. The results are shown in red for R5 viruses, magenta for R5/X4 viruses, and blue for X4 viruses.
doi:10.1371/journal.pone.0003481.g002
Figure 3. Anti-b-chemokine antibodies reverse the block to R5 HIV-1 replication in the primary in vitro response of CD4
+ T cells to
SEB. a. Goat antibodies to CCL3, CCL4, and CCL5 were added at 25 ug/ml (final concentration of each antibody) to cultures of naı ¨ve CD4
+ T cells and
autologous MDDC plus SEB in the presence of 1000 TCID50 HIV-1Ba-L and viral replication monitored on the indicated days by p24 ELISA. Controls
included cultures initiated in the absence of exogenous antibodies and cultures initiated with normal goat IgG (75 ug/ml final concentration).
Supernatant p24 concentrations are shown for duplicate cultures. b. Bivariate histograms for p24 versus CD45RO were generated as described in the
legend for Figure 1c to confirm the replication of HIV-1Ba-L in the presence of saturating concentrations of ant-b-chemokine antibodies. The data are
shown for a day 7 culture established as described in the legend to Figure 3a.
doi:10.1371/journal.pone.0003481.g003
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ligands during the primary immune response in vitro are
‘self-protected’ from concomitant R5 HIV-1 infection
The above results suggest that the individual CD4+ T cells that
secrete anti-viral CCR5 ligands might be selectively protected
from infection by R5 viruses. This ‘self-protection’ hypothesis
predicts that the synthesis of anti-viral CCR5 ligands and viral
proteins at the single cell level should tend toward mutual
exclusivity for R5 viruses but not for X4 viruses in our culture
system. Since we have to add blocking anti-beta chemokine
antibodies to establish infections with R5 viruses in the SEB
stimulated cultures; it is difficult to test this hypothesis using this
potent antigen as the readout. In preliminary studies, we found
that using weaker antigenic stimuli, such as allogeneic MDDC,
permits modest replication of R5 viruses, which allowed us to test
the hypothesis in the absence of blocking anti- b -chemokine
antibodies. The study shown in Figure 4 was carried out essentially
the same as that shown in Figure 1 except that allogeneic MDDC
were used in lieu of SEB and autologous MDDC as antigen to
elicit the primary CD4+ T cell response. Single cell analyses were
carried out on day 7 of culture by intracellular staining and flow
cytometry using fluorescent monoclonal antibodies to CCL4 and
p24 as markers for b-chemokine and HIV-1 infection, respectively.
As shown in Figure 4a, there was less apparent coincident
staining for CCL4 and p24 in cultures infected with R5 viruses
(upper panel) as compared with X4 viruses (lower panel). R5/X4
viruses were not evaluated in this series of studies. The apparent
differences in coincident CCL4 and p24 staining were evaluated
for statistical significance by calculating the ratios of CCL4
+ p24
2
cells to CCL4
+ p24
+ cells for the R5 and X4 virus panel and
analysis by a two-tailed Student’s t-test. As shown in Figure 4b, the
ratio of CCL4
+ p24
2 cells to CCL4
+ p24
+ cells ranged from 8.08
to 54.17 (mean=27.71619.24 (SD)) for R5 viruses. By contrast,
the ratio of CCL4
+ p24
2 cells to CCL4
+ p24
+ cells was
approximately 10-fold less for X4 viruses, ranging from 0.97 to
5.65 (Figure 4b, mean=2.7362.07 (SD)). This difference was
statistically significant (p=0.04) indicating a greater degree of co-
incident staining between p24 and CCL4 for the X4 viruses as
compared to the R5 viruses. Taken together, these data support
the hypothesis that CD4+ T cells which secrete anti-viral CCR5
ligands during the primary immune response in vitro are selectively
protected from infection by R5 viruses as compared with other
activated CD4
+ T cells in the same culture that do not secrete
these ligands. These data are most consistent with an autocrine
pathway of protection.
Discussion
The principal conclusion of this report is that CD4
+ T cells
which secrete anti-viral CCR5 ligands during the primary immune
response are ‘self-protected’ from R5 HIV-1 infection. This
conclusion is based on kinetic studies of HIV-1 replication during
the primary antigen specific CD4
+ T cells in vitro where R5 virus
growth was selectively dampened by the synthesis of anti-viral
CCR5 ligands by the responding T cells. It is also based on single
cell analyses of the CD4
+ T cells undergoing a primary response
where R5 HIV-1 infection and the synthesis of CCL4 were largely
exclusive. By contrast, significant exclusivity was not observed for
X4 HIV-1 infection. Taken together, these data show that CD4
+
T cells, which synthesize anti-viral CCR5 ligands during the
primary immune response, are ‘‘self-protected’’. To our knowl-
edge, this is a new phenomenon in the interplay between HIV-1
infection and anti-viral effector mechanisms of CD4
+ T cells,
which are the principal targets of this virus. Four aspects of this
observation warrant further discussion.
First, this observation strongly suggests that CD4
+ T cells
manifest potent anti-HIV-1 effector activity early in the primary
immune response in vivo. It is well established that memory CD8
+
T cells secrete high levels of anti-viral CCR5 ligands [1,7,14]
Figure 4. Exclusive expression of p24 and CCL4 in CD4+ T cells undergoing a primary immune response in the presence of R5 but
not X4 HIV-1-. a. Naı ¨ve CD4
+ T cells were cultured with allogeneic MDDC in the presence of 1000 TCID50 of the HIV-1 isolates indicated in the figure
and intracellular p24 and CCL4 staining was carried out as described in Materials and Methods on cultures harvested at day 7. b. Ratios of CCL4
+ p24
+
cells to CCL4
+ p24
2 cells were calculated for each virus shown in panel Figure 4a and the medians used to determine statistical significance between
the R5 an X4 HIV-1 groups using a two-tailed Student’s t-test.
doi:10.1371/journal.pone.0003481.g004
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mechanisms; however, less is known about the production of
these factors by CD4
+ T cell subsets during the different phases
(i.e., primary and secondary) of an immune response. In an early
study using CD45RA and CD45RO to mark naı ¨ve and memory
CD4
+ T cell subsets, respectively, it was shown that both
CD45RA
+ and CD45RO
+ subsets activated by anti-CD3 plus
anti-CD28 secreted anti-viral CCR5 ligands [23]. Our results
showing that antigen-activated naı ¨ve CD4
+ T cells secrete anti-
viral CCR5 ligands agree and extend those studies. They agree in
that both sets of studies show that recently activated naı ¨ve CD4
+ T
cells secrete anti-viral CCR5 ligands. Our studies place this
observation on a more solid footing in that the previous study used
only CD45RA expression to define naı ¨ve CD4
+ T cells. It is
known that a subset of memory CD4
+ T cells in normal
individuals also express CD45RA and that a second marker, such
as CD62L needs to be used to exclude this subset from the naı ¨ve
pool [24]. In the above experiments, naı ¨ve cells were defined as
CD4
+ CD45RO
2 CD62L
+, which excludes the CD45RA
+
population of memory CD4
+ T cells. Because of this, our studies
more precisely define the CD4
+ T cell subsets that secreted anti-
viral CCR5 ligands.
Using this marker strategy we showed previously that that
CCL4 is made by CD8
+ and CD4
+ memory T cells where greater
frequencies of CCL4
+ cells were found for the CD8
+ subsets [14].
This has been confirmed by others during vaccine evaluation [16].
By contrast, naı ¨ve CD4
+ or CD4
+ T cells did not synthesize CCL4
in short term assays [14]. However, shortly after immunization in
vitro with model antigens, naı ¨ve CD4
+ T cells differentiate into
blasts that secrete CCL3, CCL4, and CCL5 at levels that are
potently anti-viral when culture supernatants are evaluated in trans
using R5 viruses and assays using CD4
+ CCR5
+ indicator cells
[18]. This indicated that CD4
+ T cells could exert potent anti-viral
activity early in the primary immune response.
This observation led us to the current studies where we directly
challenged antigen-driven primary CD4
+ T cell responses with
R5, R5/X4, and X4 viruses to determine whether these CCR5
ligands are active in situ. In the studies described above, the viruses
were simply added at the time of culture initiation with antigen,
MDDC, and naı ¨ve CD4
+ T cells and viral growth monitored over
the course of the primary response. In all cases, strong primary
immune responses were observed to the model antigens as judged
by high frequencies of CD4
+ CD45RO
+ T cells in the stimulated
cultures. It should be noted that CD45RO expression is
upregulated within hours after antigen stimulation in our culture
system ([18] and unpublished). Thus, the presence of HIV-1
during this early phase of the immune response is not suppressive.
We used SEB and alloantigens as the immunogens because anti-
HIV-1 primary responses are small in magnitude in our system
and these responses are highly reproducible among volunteers
(unpublished). In addition, the primary alloantigen response
provided a fortuitously optimal dynamic range of response for
the bivariate analyses of CCL4 synthesis and HIV-1 infection
monitored by intracellular CCL4 and p24 expression. This raises
one caveat in that our conclusions are based on primary responses
to non-HIV-1 antigens, although it is likely that HIV-1 specific T
cells are among the spectrum of responding T cells elicited by SEB
and alloantigens.
There is another potential caveat in using superantigens as
opposed to peptide-MHC complexes (i.e., alloantigens or nominal
protein antigens) in that superantigens activated CD4
+ T cells
through both lck-dependent and lck-independent pathways
whereas peptide-MHC complexes apparently stimulate only via
the former pathway [25,26]. In this regard, it is important to note
that the key observation in the studies described above, ‘self-
protection’ of CD4
+ T cells by the synthesis anti-viral CCR5
ligands, was made using alloantigen (i.e., peptide-MHC) stimula-
tion. This tempers the caveat that the lck-independent pathway
contributes to this observation.
Second, the selective pressure exerted by anti-viral CCR5 ligands
secreted by CD4
+ T cells undergoing a primary immune response
could affect both the viral and cellular phenotypes that emerge early
inHIVinfection.Immuneresponsestodifferentviruses canresultin
distinct populations of memory T cells that differ not only in the
spectrum of their antigen receptor sequences but also surface
phenotype and effector function (reviewed in [27]). This is due to
the local ecology of the cell types infected by the virus and by
adaptationof the responding T cells to effectively confront the virus,
which attempts to escape the response by evolution under this
selective pressure. In the case of HIV-1, it has been known for some
time that distinct T cell subsets emerge during infection [28,29] and
that this is often paralleled by the emergence of viral variants with
distinct phenotypes such as altered co-receptor usage [30–32],
although the two phenomena have not been causally linked by
direct experiment. Ourstudies suggest a mechanism whereby CD4
+
T cell phenotype can affect viral phenotype and vice versa during a
primary immune response.
Since our results show that CD4
+ T cells secreting anti-viral
CCR5 ligands during the primary immune response are selectively
protected from R5 but not X4 viruses, HIV-1 specific CD4
+ T
cells with this phenotype should selectively survive during acute
infection and contribute ultimately to the memory pool. It is
interesting to note that while HIV-1 specific memory CD4
+ T cells
are selectively infected during an ongoing infection as compared
with CMV specific memory CD4
+ T cells, only a fraction of the
HIV-1 specific memory cells are infected [33]. While it is possible
that this result simply represents the stochastic nature of HIV-1
infection, it is striking that the majority of HIV-1 specific cells were
not infected. Our studies suggest that the uninfected HIV-1
specific CD4
+ T cells might be refractory to infection because they
produce anti-viral CCR5 ligands and are ‘self-protected’. If so, we
predict that HIV-1 specific memory CD4
+ T cells that survive
during infection secrete anti-viral CCR5 ligands. In this vein, a
recent report described the emergence of an unusual CD4
+
CD45RA
+ CCR7
2 CCR5
+ memory population in infected people
that is resistant to HIV-1 infection [34]. It will be interesting to
learn whether these memory cells derive from the lineage of CD4
+
T cells that secrete anti-viral CCR5 ligands during the primary
immune response.
Third, it is possible that the synthesis of anti-viral CCR5 ligands
early in the primary immune response contributes a selective
pressure to generate the latent viral reservoir in resting CD4
+ T
cells [35,36]. The CD4
+ T cell reservoir latent harboring HIV-1 is
established very early in infection [37,38] and it persists
throughout the course of infection [39,40] with apparent
replenishment even in individuals undergoing successful HAART
therapy [39,40]. Furthermore, this latent pool is populated
predominantly by R5 viruses [41]. Viral latency is one means to
escape selective pressure and it is tempting to speculate that the
selective pressure exerted by anti-viral CCR5 ligands early in the
primary immune response contributes to the early establishment of
the latent pool of R5 HIV-1. This hypothesis is currently under
investigation using our system.
Fourth, our studies also suggest a mechanism that could drive
the co-receptor switch early in infection. It is well established that
the co-receptor switch can occur rapidly in scid-Hu mice under
the selective pressure of CCL5 [42] and it is reasonable to suspect
that a similar switch could occur in vivo under pressure of CCL5
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+ T cells undergoing a primary
immune response. We are testing this hypothesis in our system
where delayed viral growth is observed for some R5 virus isolates
such as HIV-1SF162 (Figure 1a). This virus might be particularly
susceptible to co-receptor switching as it has been shown that it has
a single pathway to X4 usage that is determined by two common
mutations in the V3 loop (I309R and A316V) regardless of
whether the selection pressure was exerted by culturing in the
presence of CCL5 or by switching cellular substrates [42]. Thus, it
is possible that the HIV-1SF162 that appears late in our culture
system is actually co-receptor switched. We are testing this
hypothesis but the potent secretion of anti-viral CCL5 ligands in
the early primary CD4
+ T cell response in vitro [18] coupled with
the selective protection of the CD4
+ T cells that synthesize these
ligands, strongly suggests a role for anti-viral chemokines in
protection against R5 viruses early in infection.
In summary, the results described above indicate a previously
overlooked aspect of protective immunity against HIV-1, the
selective protection of CD4
+ T cells that secrete anti-viral CCR5
ligands during the primary immune response. At this point, our
studies are limited to a model system in which naı ¨ve CD4
+ T cells
are co-cultured with MDDC and an antigen to elicit a primary
immune response. Our studies suggest that HIV specific CD4
+ T
cells that secrete anti-viral CCL5 ligands should be selectively
protected during the primary HIV-1 infection and enter the
memory pool. It is also possible that the relative survival of these
cells is a determining factor in the relationship between the
magnitude of early CD4
+ T cell depletion and clinical outcome in
SHIV vaccination models [43]. Most important, these conclusions
suggest that the design immunogens which selectively elicit CD4
+
T cell responses capable of ‘‘self-protection’’ against HIV-1 is a
potential new strategy in the quest for an AIDS vaccine.
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